{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:41Z","timestamp":1760145701696,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We investigated whether developing an autoimmune disorder (AID) following a high-grade epithelial ovarian cancer diagnosis improves overall survival. This retrospective study included data from women treated for high-grade serous, endometrioid, or transitional cell ovarian, fallopian tube, or peritoneal cancer FIGO stage III or IV at a Swiss cantonal gynecological cancer center (2008\u20132023). We used Kaplan\u2013Meier estimates and the Cox proportional hazards model using time-varying covariates for the survival function estimation. In all, 9 of 128 patients developed an AID following a cancer diagnosis. The median time from cancer diagnosis to AID was 2 years (IQR 2\u20135). These women survived for a median of 3031 days (IQR 1765\u20133963) versus 972 days (IQR 568\u20131819) for those who did not develop an AID (p = 0.001). The median overall survival of nine women with a pre-existing AID was 1093 days (IQR 716\u20131705), similar to those who never had an AID. The multivariate analyses showed older age (p = 0.003, HR 1.04, 95% CI 1.013\u20131.064) was associated with a poorer prognosis, and developing an AID after a cancer diagnosis was associated with longer survival (p = 0.033, HR 0.113, 95% CI 0.015\u20130.837). Clinical manifestations of autoimmune disorders following ovarian cancer diagnoses were associated with better overall survival (8 versus 2.7 years), indicating an overactive immune response may improve cancer control.<\/jats:p>","DOI":"10.3390\/curroncol31080344","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:20:51Z","timestamp":1723627251000},"page":"4613-4623","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2021-3208","authenticated-orcid":false,"given":"Ana\u00efs","family":"Fr\u00f6hlich","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoEllen","family":"Welter","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabell","family":"Witzel","sequence":"additional","affiliation":[{"name":"Department of Gynecology, University Hospital Z\u00fcrich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7902-6300","authenticated-orcid":false,"given":"Julia","family":"Voppichler","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2167-3508","authenticated-orcid":false,"given":"Mathias K.","family":"Fehr","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian Cancer in the World: Epidemiology and Risk Factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Harter","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_4","unstructured":"(2024, June 25). Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality\u2014All COD, Aggregated with State, Total U.S. (1969\u20132020) <Katrina\/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Released September 2022. Underlying Mortality Data Provided by NCHS, Available online: www.cdc.gov\/nchs."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.34350","article-title":"Real-life Data on Treatment and Outcomes in Advanced Ovarian Cancer: An Observational, Multinational Cohort Study (RESPONSE Trial)","volume":"128","author":"Marth","year":"2022","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The Forefront of Ovarian Cancer Therapy: Update on PARP Inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","unstructured":"Deutsche Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e.V (2024, June 25). (DGGG) S3-Leitlinie Diagnostik, Therapie und Nachsorge Maligner Ovarialtumoren 2022. Available online: https:\/\/awmf.org."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.7150\/jca.47695","article-title":"Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer","volume":"12","author":"Liu","year":"2021","journal-title":"J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.18632\/oncotarget.14919","article-title":"The Prognostic Value of Tumor-Infiltrating T Lymphocytes in Ovarian Cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","unstructured":"Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C., Gentry-Maharaj, A., Toloczko, A., and Hein, A. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol., 3, e173290."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti\u2013PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2018.36.15_suppl.5511","article-title":"Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Interim Results from the Phase 2 KEYNOTE-100 Study","volume":"36","author":"Matulonis","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in Patients with Programmed Death Ligand 1-Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab Alone or in Combination with Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study","volume":"22","author":"Fujiwara","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without Avelumab Followed by Avelumab Maintenance versus Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Duranti, S., Pietragalla, A., Daniele, G., Nero, C., Ciccarone, F., Scambia, G., and Lorusso, D. (2021). Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers, 13.","DOI":"10.3390\/cancers13092089"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e002873","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological Configuration of Ovarian Carcinoma: Features and Impact on Disease Outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab Combined with Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE\/ENGOT-Ov29 Trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brodeur, M.N., Dopeso, H., Zhu, Y., Longhini, A.L.F., Gazzo, A., Sun, S., Koche, R., Qu, R., Hamard, P.-J., and Bykov, Y. (2023). Interferon Response and Epigenetic Modulation by SMARCA4 Mutations Drive Ovarian Tumor Immunogenicity. bioRxiv.","DOI":"10.1101\/2023.08.08.552544"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, Prevalence, and Co-Occurrence of Autoimmune Disorders over Time and by Age, Sex, and Socioeconomic Status: A Population-Based Cohort Study of 22 Million Individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.12.024","article-title":"History of Autoimmune Disease and Long-Term Survival of Epithelial Ovarian Cancer: The Extreme Study","volume":"182","author":"Hannibal","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1002\/cam4.5989","article-title":"Survival in Elderly Patients with Breast Cancer with and without Autoimmune Disease","volume":"12","author":"Dedousis","year":"2023","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/ijgc-2022-003570","article-title":"Do Autoimmune Diseases Influence the Onset and Progression of Ovarian Cancer? A Systematic Review and Meta-Analysis","volume":"32","author":"Wouters","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous Adverse Events and Cancer Survival Prognosis with Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-Related Adverse Events: Promising Predictors for Efficacy of Immune Checkpoint Inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaad.2022.09.012","article-title":"Dermatology Evaluation for Cutaneous Immune-Related Adverse Events Is Associated with Improved Survival in Cancer Patients Treated with Checkpoint Inhibition","volume":"88","author":"Jacoby","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/COC.0000000000000408","article-title":"\u201cLost to Follow-up\u201d among Adult Cancer Survivors","volume":"41","author":"Gill","year":"2018","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:35:41Z","timestamp":1760110541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["curroncol31080344"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31080344","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}